Stockscreener 앱 받기
8.89
1.25%
0.11
시간 외 거래:
8.88
-0.010
-0.11%
전일 마감가:
$8.78
열려 있는:
$8.78
하루 거래량:
1.20M
Relative Volume:
0.96
시가총액:
$607.87M
수익:
-
순이익/손실:
$-297.11M
주가수익비율:
-2.0297
EPS:
-4.38
순현금흐름:
$-216.95M
1주 성능:
-32.14%
1개월 성능:
-44.71%
6개월 성능:
-15.65%
1년 성능:
+18.53%
1일 변동 폭
$8.495
$9.10
1주일 범위
$8.495
$13.32
52주 변동 폭
$6.065
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| PHAT | 8.89 | 607.87M | 0 | -297.11M | -216.95M | -4.38 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-09 | 개시 | H.C. Wainwright | Buy |
| 2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-13 | 개시 | Craig Hallum | Buy |
| 2022-10-21 | 개시 | Jefferies | Buy |
| 2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2021-02-17 | 개시 | BMO Capital Markets | Outperform |
| 2021-02-02 | 개시 | Guggenheim | Buy |
| 2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-11-20 | 개시 | Evercore ISI | Outperform |
| 2019-11-19 | 개시 | Goldman | Neutral |
| 2019-11-19 | 개시 | Jefferies | Buy |
| 2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
(PHAT) Proactive Strategies - Stock Traders Daily
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Up 115.60% This Year: What Is Going To Happen Next - Stocks Register
Phathom Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Business Updates - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.9%Here's What Happened - MarketBeat
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlig - GuruFocus.com
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Phathom Pharmaceuticals Reports Significant Revenue Growth - TipRanks
Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Previ - GuruFocus.com
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance
Jennison Associates LLC's Strategic Acquisition in Phathom Pharm - GuruFocus.com
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96% - Yahoo Finance
Phathom Pharmaceuticals (PHAT) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat
PHAT SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action InvestigationPHAT - Marketscreener.com
Phathom Pharmaceuticals to Report Third Quarter 2024 - GlobeNewswire
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business - The Bakersfield Californian
Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 - StockTitan
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the - GlobeNewswire
Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting - Yahoo Finance
Where are the Opportunities in (PHAT) - Stock Traders Daily
Some of the Gastroesophageal Reflux Disease Therapeutics market players are: - InsightAce Analytic
Shareholders have faith in loss-making Phathom Pharmaceuticals (NASDAQ:PHAT) as stock climbs 6.6% in past week, taking one-year gain to 74% - Simply Wall St
Creative Planning Has $278,000 Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 6.8%Time to Buy? - MarketBeat
Certain Common Stock of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-OCT-2024. - Marketscreener.com
Phathom Pharmaceuticals Inc [PHAT] Investment Appeal on the Rise - Knox Daily
A year in review: Phathom Pharmaceuticals Inc (PHAT)’s performance in the last year - US Post News
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.4%Time to Sell? - MarketBeat
PHAT’s 52-Week Rollercoaster: From $6.07 to $19.71 – What’s Next for Investors? - The InvestChronicle
Financial Health Report: Phathom Pharmaceuticals Inc (PHAT)’s Ratios Tell a Tale - The Dwinnex
Learn to Evaluate (PHAT) using the Charts - Stock Traders Daily
A stock that deserves closer examination: Phathom Pharmaceuticals Inc (PHAT) - US Post News
PHAT Stock Sees Decline of Approximately -13.44% in Last Five Days - Knox Daily
PHAT Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
PHAT (Phathom Pharmaceuticals Inc) may reap gains as insiders became active recently - Knox Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 7.5%Here's What Happened - MarketBeat
Daily Market Movement: Phathom Pharmaceuticals Inc (PHAT) Sees a -4.96 Decrease, Closing at 17.25 - The Dwinnex
A new trading data show Phathom Pharmaceuticals Inc (PHAT) is showing positive returns. - SETE News
Marshall Wace LLP Invests $1.16 Million in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals Inc Inc. (PHAT) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 4.8%Here's Why - MarketBeat
The Potential Rise in the Price of Phathom Pharmaceuticals Inc (PHAT) following insiders activity - Knox Daily
Have you been able to find a good deal on Phathom Pharmaceuticals Inc’s shares? - US Post News
Phathom Pharmaceuticals Inc (PHAT)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Its Stock Has Paid Off Big Time For Phathom Pharmaceuticals Inc - SETE News
Phathom Pharmaceuticals Inc (PHAT)’s stock chart: A technical perspective - US Post News
Phathom's Voquezna: A Breakthrough Drug Facing Marketing Challenges (NASDAQ:PHAT) - Seeking Alpha
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) - PR Newswire
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):